右佐匹克隆与氯硝西泮辅助治疗精神分裂症睡眠障碍对照研究
Comparative study between eszopiclone and clonazepam in adjuvant treatment of sleep disorders of schizophrenia
王刚平 1颉瑞 1裴根祥 1杜鹤宇 1李宏1
作者信息
- 1. 天水市精神病医院,甘肃,天水,741000
- 折叠
摘要
目的 探讨右佐匹克隆辅助治疗精神分裂症睡眠障碍的疗效及安全性.方法 91例伴睡眠障碍的精神分裂症患者(均统一服用阿立哌唑10～20 mg·d-1)随机分成2组,分别口服右佐匹克隆3～6 mg·d-1(n=45)或氯硝西泮2～4 mg·d-1(n=46),采用匹兹堡睡眠质量指数(PSQI)、阳性和阴性症状量表(PANSS)、副反应量表(TESS)评定疗效和安全性;观察3 wk.结果 2组各完成43例.治疗3 wk后,2组睡眠时间均显著延长,PSQI评分和PANSS评分显著下降(均P＜0.01),2组间疗效无显著差异(P＞0.05);右佐匹克隆组日间功能障碍的改善显著优于氯硝西泮组[(1.2±0.9)分vs.(1.6±0.7)分,P＜0.05];2组TESS评分无显著差异(P＞0.05),右佐匹克隆组嗜睡、头昏的发生率显著少于氯硝西泮组(P＜0.05).结论 右佐匹克隆辅助治疗精神分裂症睡眠障碍疗效显著,安全性优于氯硝西泮.
Abstract
AIM To detect the clinical efficacy and safety of eszopiclone in the adjuvant treatment of sleep disorders of schizophrenia.METHODS Ninety-one schizophrenic patients with sleep disorders who received aripiprazole 10 - 20 mg·d-1 were divided into two groups, 45 for eszopiclone (3 - 6 mg·d-1) group and 46 for clonazepam (2 - 4 mg·d-1) group.PSQI、 PANSS and TESS were used to evaluate the efficacy and safety of the 3-week treatment.RESULTS The two groups completed 43 patients for each.By the end of the treatment, the sleep duration increased and the PSQI scores and PANSS scores of the two groups decreased significantly (all P ＜ 0.01 ), and there was no significant difference in the overall efficacy between the two groups (P ＞ 0.05).But the ezopiclone group had better effect on treating daytime dysfunction than the clonazepam group [( 1.2± 0.9) vs.( 1.6 ± 0.7), P ＜ 0.05].There was no significant difference in the TESS scores between the two groups (P ＞ 0.05) , but the incidence rates of somnolence and dizziness in the eszopiclone group were lower than that of the clonazepam group (P ＜ 0.05).CONCLUSION Eszopiclone has significant effects on the treatment of sleep disorders of schizophrenia, and it is more secure than clonazepam.
关键词
右佐匹克隆/氯硝西泮/精神分裂症/睡眠障碍/临床对照试验引用本文复制引用
出版年
2011
NETL
NSTL
维普
万方数据